AbbVie (TSX:ABBV) Stock Based Compensation: C$1,360 Mil (TTM As of Mar. 2026)


TSX:ABBV AbbVie Inc TSX:ABBV
81 GF Score
Price C$35.51
GF Value C$29.99
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Stock Based Compensation?

AbbVie TSX:ABBV -3.79% 81 Stock Based Compensation is C$1,360 Mil as of Mar. 2026. GuruFocus rates TSX:ABBV with a GF Score™ of 81/100 and a GF Value™ of C$29.99 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's Stock Based Compensation for the three months ended in Mar. 2026 was C$609 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was C$1,360 Mil.

AbbVie Stock Based Compensation Related Terms

AbbVie Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for AbbVie's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Stock Based Compensation Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 885.76 911.55 1,002.18 1,297.90 1,317.42

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 588.60 244.66 289.13 216.58 609.17
TSX:ABBV
81GF Score
AbbVie Inc TSX:ABBV
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1,360 Mil.

What does a Stock Based Compensation of C$1,360 Mil mean?
AbbVie (TSX:ABBV) has a Stock Based Compensation of C$1,360 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for AbbVie and its competitors.
Is AbbVie's Stock Based Compensation too high?
AbbVie's current Stock Based Compensation is C$1,360 Mil. Overall, AbbVie has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Stock Based Compensation compare to MRK and JNJ?
AbbVie's Stock Based Compensation of C$1,360 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for AbbVie and its competitors. AbbVie's current Stock Based Compensation is C$1,360 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (TSX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is C$29.99, compared to a current price of C$35.51 — trading 18.4% above its estimated fair value. The current Stock Based Compensation is C$1,360 Mil. AbbVie's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For AbbVie (TSX:ABBV), the current Stock Based Compensation is C$1,360 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (TSX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of C$35.51 is trading 18.4% above its estimated GF Value™ of C$29.99. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for TSX:ABBV:

  • Stock Based Compensation: C$1,360 Mil
  • GF Value™: C$29.99 vs. price of C$35.51 (18.4% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the TSX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
81GF Score

Get the complete analysis for TSX:ABBV

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$35.51
Price
C$29.99
GF Value